Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

151.40 +0.28 (+0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

51 52 Next >

What Does Gilead Sciences' Debt Look Like? ↗

April 27, 2023

Via Benzinga

Better Buy: Pfizer vs. Gilead ↗

April 27, 2023

Pfizer and Gilead look cheap right now.

Via The Motley Fool

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today ↗

April 26, 2023

Via Benzinga

3 Cash-Rich Biotech Stocks to Bet on for the Long Haul ↗

April 25, 2023

Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch.

Via InvestorPlace

This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗

April 25, 2023

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

Via The Motley Fool

2 Excellent Dividend Stocks to Buy for Less Than $100 ↗

April 25, 2023

Both companies are steals at current levels.

Via The Motley Fool

Expert Ratings for Gilead Sciences ↗

April 12, 2023

Via Benzinga

Could Gilead Sciences Stock Help You Become a Millionaire? ↗

April 12, 2023

The company's dominant HIV therapies and growing oncology pipeline are delivering.

Via The Motley Fool

P/E Ratio Insights for Gilead Sciences ↗

April 11, 2023

Via Benzinga

A Look Into Gilead Sciences' Debt ↗

April 11, 2023

Via Benzinga

Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades' ↗

April 21, 2023

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc.

Via Benzinga

Strong Quant Screens Say These 7 Growth Stocks Are a Buy ↗

April 19, 2023

StockRover’s quant screen is a grading system that brings up rewarding growth stocks to buy for income investors.

Via InvestorPlace

Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗

April 18, 2023

On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.

Via Benzinga

3 Dividend Stocks to Buy and Hold for the Next Decade ↗

April 15, 2023

Long-term investors looking for income should especially like these stocks.

Via The Motley Fool

6 Reasons to Buy Gilead Sciences Stock ↗

April 06, 2023

The healthcare stock could be a solid pillar to build your portfolio around.

Via The Motley Fool

Dividend Income Update March 2023 ↗

April 12, 2023

It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio.

Via Talk Markets

If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today ↗

April 10, 2023

Would you have been better off investing in the S&P 500?

Via The Motley Fool

Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗

April 10, 2023

The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.

Via Benzinga

3 Dividend Stocks Billionaires Seem to Love ↗

April 09, 2023

It sometimes pays to follow the lead of successful people.

Via The Motley Fool

Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough ↗

April 06, 2023

Via Benzinga

GILD - Chart Of The Week ↗

April 05, 2023

The daily chart looks pretty strong right now. The stock is trying to break through the resistance line that started around the beginning of December.

Via Talk Markets

Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags ↗

April 03, 2023

It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.

Via Talk Markets

Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis ↗

March 31, 2023

A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),...

Via Benzinga

COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All ↗

March 31, 2023

Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many...

Via Benzinga

ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash ↗

March 31, 2023

Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the...

Via Benzinga

Is It Time to Buy These Ultra-Cheap Dividend Stocks? ↗

March 29, 2023

These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles.

Via The Motley Fool

Why Are Cathie Wood's Ark ETFs Still Trailing Nasdaq Stocks? ↗

March 29, 2023

From their all-time highs towards the end of 2021, tech stocks have suffered a significant blow from the Federal Reserve's interest rate hike cycle.

Via Benzinga

Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run ↗

March 29, 2023

Viking Therapeutics stock might in the midst of a historic run.

Via The Motley Fool

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields ↗

March 27, 2023

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Bunge, Gilead Sciences And A Famous Chocolate Maker On CNBC's 'Final Trades' ↗

March 27, 2023

On CNBC’s "Halftime Report Final Trades," JP Morgan Private Bank’s Anastasia Amoroso said she is sticking with Invesco QQQ Tru

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gilead Sciences (NQ:GILD)

Headline News about Gilead Sciences

Starting at $3.75/week.

Subscribe Today